Nektar Therapeutics
Find Ratings ReportsNEKTAR THERAPEUTICS's gross profit margin for the fourth quarter of its fiscal year 2023 has decreased when compared to the same period a year ago. Sales and net income have grown, and although the growth in revenues has outpaced the average competitor within the subsector, the net income growth has not. NEKTAR THERAPEUTICS is extremely liquid. Currently, the Quick Ratio is 5.95 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has significantly decreased by 64.27% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q4 FY23 | Q4 FY22 |
---|---|---|
Net Sales ($mil) | 23.89 | 22.02 |
EBITDA ($mil) | 0.0 | -37.71 |
EBIT ($mil) | -30.66 | -40.89 |
Net Income ($mil) | -42.08 | -59.69 |
Balance Sheet | Q4 FY23 | Q4 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 303.62 | 504.98 |
Total Assets ($mil) | 398.03 | 710.6 |
Total Debt ($mil) | 230.4 | 286.87 |
Equity ($mil) | 130.99 | 366.64 |
Profitability | Q4 FY23 | Q4 FY22 |
---|---|---|
Gross Profit Margin | 69.51 | 86.15 |
EBITDA Margin | 0.0 | -171.21 |
Operating Margin | -128.37 | -185.66 |
Sales Turnover | 0.23 | 0.13 |
Return on Assets | -69.35 | -51.81 |
Return on Equity | -210.75 | -100.43 |
Debt | Q4 FY23 | Q4 FY22 |
---|---|---|
Current Ratio | 6.45 | 8.0 |
Debt/Capital | 0.64 | 0.44 |
Interest Expense | 6.87 | 7.2 |
Interest Coverage | -4.46 | -5.68 |
Share Data | Q4 FY23 | Q4 FY22 |
---|---|---|
Shares outstanding (mil) | 190.77 | 188.56 |
Div / share | 0.0 | 0.0 |
EPS | -0.22 | -0.32 |
Book value / share | 0.69 | 1.94 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 1668212.0 | 1511600.0 |
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 1.25 indicates a significant discount versus the S&P 500 average of 4.68 and a significant discount versus the subsector average of 19.07. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount. After reviewing these and other key valuation criteria, NEKTAR THERAPEUTICS proves to trade at a discount to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NKTR NM | Peers 85.83 | NKTR NA | Peers 38.76 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. NKTR's P/E is negative making this valuation measure meaningless. |
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures. Ratio not available. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
NKTR NM | Peers 18.08 | NKTR NA | Peers 1.16 | |||||||||||||||||||||
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings. NKTR's ratio is negative making this valuation measure meaningless. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
NKTR 1.25 | Peers 19.07 | NKTR 25.89 | Peers 12.58 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. NKTR is trading at a significant discount to its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. NKTR is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
NKTR 1.82 | Peers 84.44 | NKTR -2.10 | Peers 42.35 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. NKTR is trading at a significant discount to its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. NKTR significantly trails its peers on the basis of sales growth. |
|||||||||||||||||||||||